Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX22 and HLX87 in HER2-Positive Recurrent or Metastatic Breast Cancer
NCT07294508Phase 3Recruiting
- Sponsor
- Henlius
- Start
- Feb 2026
- Primary completion
- Jan 2028
- Modality
- Prophylactic Vaccines, Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of hlx22, gq1005 in breast cancer, sponsored by Henlius. Started Feb 2026; status: recruiting.
02
Drugs
hlx22gq1005
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07294508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294508.